Clinical Trial

Safety for Home Administration of Microdose Psilocybin Use

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this laboratory study is to establish whether and which microdoses of psilocybin are safe to administer at home to healthy participants. Eligible participants will be given ascending doses of psilocybin trihydrate and a single, interspersed, randomized placebo on separate days in double-blind fashion. The participants will be asked to complete questionnaires and undergo safety assessments.
Protocol Amendment History 4 changes
critical Trial completed 2026-08-15
notable Enrollment reduced: 20 -> 17 participants 2026-08-15
notable Primary completion pushed: 2026-07 -> 2026-07-31 2026-08-15
minor Completion moved earlier: 2027-07 -> 2026-07-31 2026-08-15
Trial Details
NCT Number NCT06450210
Lead Sponsor Johns Hopkins University
Collaborators: Private Philanthropic Funds
Conditions Psychedelic Experiences
Enrollment 17 participants
Start Date 2024-12-06
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-14